CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

Compare

50 Followers

CAMP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.31 - $12.30

Previous Close$4.45

Volume38.22K

Average Volume (3M)122.76K

Market Cap

$35.08M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.80

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding20,161,074

10 Day Avg. Volume104,834

30 Day Avg. Volume122,764

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$15.25

Price Target Upside813.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial MilestonesCAMP is eligible for up to $35mm in development/regulatory milestones, $35mm in sales milestones, and tiered royalties from mid-single digits to low double digits.

Market OpportunityCAMP's lead candidate targets a $1B market, addressing urea cycle disorders (UCDs) affecting approximately 20k U.S. and EU patients with no disease modifying treatments available.

Technology PlatformStrong potential in CAMP's proprietary RNA-based technology platform to target a wide spectrum of haploinsufficient diseases, where effective treatments are not available and a modest increase in target gene expression can lead to meaningful clinical benefit.

Bears Say

Operational CostsSG&A expenses of $4.7 million were above expectations, suggesting higher than anticipated operational costs.

Share Price PerformanceThe weakness in share price since the Oct. '24 IPO with no fundamental changes reflects the significant challenges faced by early-stage biotech companies developing genetic medicines.

CAMP4 Therapeutics Corporation News

CAMP4 Elects Directors and Ratifies Auditor

CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an announcement. On June 11, 2025, CAMP4 Therapeutics Corporation held...

2M ago

CAMP

Camp4 Therapeutics initiated with an Outperform at Wedbush

Wedbush analyst Yun Zhong initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $8 price target...

2M ago

CAMP

Camp4 Therapeutics initiated with an Outperform at Wedbush

Wedbush initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $8 price target Published first on...

2M ago

CAMP

CAMP4 Therapeutics Unveils Promising Data at ASGCT 2025

CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an announcement. On May 16, 2025, CAMP4 Therapeutics presented promising...

3M ago

CAMP

Camp4 Therapeutics delivers three presentantions on SYNGAP1-related disorders

CAMP4 Therapeutics (CAMP) delivered three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders, or UCDs, programs...

3M ago

CAMP

CAMP4 Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

Analyst Mani Foroohar of Leerink Partners reiterated a Buy rating on CAMP4 Therapeutics Corporation (CAMP – Research Report),...

3M ago

CAMP

Camp4 Therapeutics reports Q1 EPS (62c), consensus (70c)

Reports Q1 revenue $858M, consensus $33.33K. “We are very pleased with the strong execution during the first quarter...

3M ago

CAMP

CAMP4 Therapeutics Advances RNA-Based Therapeutics

CAMP4 Therapeutics Corporation ( ($CAMP) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

CAMP

Promising Developments and Solid Financials Support Buy Rating for CAMP4 Therapeutics

Analyst Mani Foroohar of Leerink Partners reiterated a Buy rating on CAMP4 Therapeutics Corporation (CAMP – Research Report),...

4M ago

CAMP

CAMP4 Therapeutics Expands Board with New Director Appointments

An announcement from CAMP4 Therapeutics Corporation ( ($CAMP) ) is now available. On March 12, 2025, CAMP4 Therapeutics...

4M ago

CAMP

Camp4 Therapeutics appoints Williams, Stewart to board of directors

CAMP4 Therapeutics (CAMP) announced the appointments of Doug Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company’s...

4M ago

CAMP

Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25

CAMP4 Therapeutics (CAMP) provided corporate updates and key objectives for 2025. “2024 was a transformative year for CAMP4,...

7M ago

CAMP

Camp4 Therapeutics appoints Maraganore, Meyers are strategic advisors

CAMP4 Therapeutics (CAMP) announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to...

8M ago

CAMP

CAMP4 Therapeutics Corp trading resumes

15:36 EST CAMP4 Therapeutics (CAMP) Corp trading resumes Published first on TheFly – the ultimate source for real-time,...

8M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $12.30 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $35.08M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on Mar 27, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.862 by $0.092.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 20,161,074 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.862. Following the earnings report the stock price went down -7.921%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

CAMP4 Therapeutics Corporation Stock Smart Score

Neutral

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

CAMP Earnings Data >

CAMP Stock 12 Month Forecast

Average Price Target

$15.25

▲(813.17%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,3.12,4.359999999999999,5.6,6.84,8.08,9.32,10.559999999999999,11.8,13.04,14.280000000000001,15.52,16.759999999999998,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.9084615384615384,3.936923076923077,4.9653846153846155,5.993846153846154,7.022307692307693,8.05076923076923,9.079230769230769,10.107692307692307,11.136153846153846,12.164615384615384,13.193076923076923,14.221538461538461,{"y":15.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,2.3507692307692305,2.8215384615384616,3.292307692307692,3.763076923076923,4.233846153846153,4.704615384615384,5.1753846153846155,5.646153846153846,6.116923076923077,6.587692307692308,7.058461538461539,7.529230769230769,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.75,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >